Vext Science Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 2/6
Vext Science has been growing earnings at an average annual rate of 25%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 14.7% per year. Vext Science's return on equity is 7.1%, and it has net margins of 14.6%.
Key information
25.0%
Earnings growth rate
9.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 14.7% |
| Return on equity | 7.1% |
| Net Margin | 14.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vext Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 35 | 5 | 8 | 0 |
| 30 Jun 23 | 34 | 7 | 8 | 0 |
| 31 Mar 23 | 34 | 8 | 10 | 0 |
| 31 Dec 22 | 35 | 11 | 10 | 0 |
| 30 Sep 22 | 37 | 6 | 9 | 0 |
| 30 Jun 22 | 38 | 6 | 7 | 0 |
| 31 Mar 22 | 39 | 6 | 7 | 0 |
| 31 Dec 21 | 37 | 5 | 6 | 0 |
| 30 Sep 21 | 34 | 5 | 6 | 0 |
| 30 Jun 21 | 33 | 5 | 6 | 0 |
| 31 Mar 21 | 30 | 4 | 5 | 0 |
| 31 Dec 20 | 25 | 2 | 5 | 0 |
| 30 Sep 20 | 22 | 0 | 6 | 0 |
| 30 Jun 20 | 20 | 0 | 6 | 0 |
| 31 Mar 20 | 20 | 0 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 5 | 0 |
| 30 Sep 19 | 23 | 4 | 4 | 0 |
| 30 Jun 19 | 23 | 5 | 4 | 0 |
| 31 Mar 19 | 21 | 4 | 3 | 0 |
| 31 Dec 18 | 18 | 4 | 3 | 0 |
| 31 Dec 17 | 15 | 4 | 2 | 0 |
Quality Earnings: VEXT.F has high quality earnings.
Growing Profit Margin: VEXT.F's current net profit margins (14.6%) are lower than last year (15.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VEXT.F's earnings have grown significantly by 25% per year over the past 5 years.
Accelerating Growth: VEXT.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VEXT.F had negative earnings growth (-11.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13.2%).
Return on Equity
High ROE: VEXT.F's Return on Equity (7.1%) is considered low.